Back to today’s briefing

Story perspectives

Aficamten Outshines Metoprolol, Sparks 34% Stock Surge

9/3/2025

45 4

Summary

Story summary

Cytokinetics reported Phase 3 MAPLE-HCM results, showing aficamten outperformed metoprolol for obstructive hypertrophic cardiomyopathy, causing a 34% stock surge in Europe.
The trial included 175 patients, showing enhanced exercise capacity and heart function.
Significant funding and guideline updates are necessary for aficamten's market entry.
The company aims to seek FDA approval by December 2025.

1 of 1

Story summary

Cytokinetics reported Phase 3 MAPLE-HCM results, showing aficamten outperformed metoprolol for obstructive hypertrophic cardiomyopathy, causing a 34% stock surge in Europe.
The trial included 175 patients, showing enhanced exercise capacity and heart function.
Significant funding and guideline updates are necessary for aficamten's market entry.
The company aims to seek FDA approval by December 2025.